ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Recurrence
Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Nashville, TN, USA:

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin...

Enrolling
Lymphoma
Lymphoma, Non Hodgkin
Drug: TLN-254
Drug: TLN-121

Phase 1

Treeline Biosciences, Inc.

Nashville, Tennessee, United States and 11 other locations

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 m-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393
Drug: Glofitamab

Phase 1

Arvinas
Arvinas

Nashville, Tennessee, United States and 16 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Nashville, Tennessee, United States and 41 other locations

at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...

Active, not recruiting
Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: cemsidomide

Phase 1

C4 Therapeutics

Nashville, Tennessee, United States and 12 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Nashville, Tennessee, United States and 37 other locations

safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non...

Enrolling
B-cell Non-Hodgkin Lymphoma
Drug: AZD4512

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Franklin, Tennessee, United States and 20 other locations

in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized ster...

Enrolling
B-Cell Non-Hodgkins Lymphoma
Drug: Glofitamab
Drug: Gemcitabine

Phase 2

Roche
Roche

Nashville, Tennessee, United States and 50 other locations

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed orig...

Enrolling
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib

Phase 4

Lilly
Lilly

Nashville, Tennessee, United States and 34 other locations

and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non...

Enrolling
Marginal Zone Lymphoma (MZL)
Follicular Lymphoma ( FL)
Biological: LTZ-301

Phase 1

LTZ Therapeutics, Inc.

Nashville, Tennessee, United States and 4 other locations

of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse...

Enrolling
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Biological: Prizloncabtagene autoleucel (Prizlo-Cel)

Phase 1, Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Nashville, Tennessee, United States and 30 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems